These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 25835624)
1. Role of the technical aspects of hypofractionated radiation therapy treatment of prostate cancer: a review. Clemente S; Nigro R; Oliviero C; Marchioni C; Esposito M; Giglioli FR; Mancosu P; Marino C; Russo S; Stasi M; Strigari L; Veronese I; Landoni V Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):182-95. PubMed ID: 25835624 [TBL] [Abstract][Full Text] [Related]
2. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients. Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386 [TBL] [Abstract][Full Text] [Related]
3. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy. Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939 [TBL] [Abstract][Full Text] [Related]
4. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes. Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418 [TBL] [Abstract][Full Text] [Related]
5. Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer. Wahl M; Descovich M; Shugard E; Pinnaduwage D; Sudhyadhom A; Chang A; Roach M; Gottschalk A; Chen J Technol Cancer Res Treat; 2017 Apr; 16(2):178-187. PubMed ID: 27199276 [TBL] [Abstract][Full Text] [Related]
6. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer. Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807 [TBL] [Abstract][Full Text] [Related]
7. Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. Vesprini D; Catton C; Jacks L; Lockwood G; Rosewall T; Bayley A; Chung P; Gospodarowicz M; Ménard C; Milosevic M; Nichol A; Skala M; Warde P; Bristow RG Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):608-16. PubMed ID: 22099034 [TBL] [Abstract][Full Text] [Related]
8. Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial. Katayama S; Striecker T; Kessel K; Sterzing F; Habl G; Edler L; Debus J; Herfarth K Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):926-33. PubMed ID: 25216858 [TBL] [Abstract][Full Text] [Related]
9. Prostate hypofractionated radiation therapy with injection of hyaluronic acid: acute toxicities in a phase 2 study. Chapet O; Decullier E; Bin S; Faix A; Ruffion A; Jalade P; Fenoglietto P; Udrescu C; Enachescu C; Azria D Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):730-6. PubMed ID: 25752385 [TBL] [Abstract][Full Text] [Related]
10. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Luxton G; Hancock SL; Boyer AL Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924 [TBL] [Abstract][Full Text] [Related]
11. Three-dimensional conformal radiotherapy for early stage prostatic cancer: techniques, outcomes, and possible pitfalls. Dipetrillo TA Surg Oncol Clin N Am; 2000 Jul; 9(3):435-53, viii. PubMed ID: 10853135 [TBL] [Abstract][Full Text] [Related]
12. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy. Myrehaug S; Chan G; Craig T; Weinberg V; Cheng C; Roach M; Cheung P; Sahgal A Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e657-62. PubMed ID: 22245189 [TBL] [Abstract][Full Text] [Related]
13. Intrafraction prostate translations and rotations during hypofractionated robotic radiation surgery: dosimetric impact of correction strategies and margins. van de Water S; Valli L; Aluwini S; Lanconelli N; Heijmen B; Hoogeman M Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1154-60. PubMed ID: 24661668 [TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. King CR; Brooks JD; Gill H; Presti JC Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):877-82. PubMed ID: 21300474 [TBL] [Abstract][Full Text] [Related]
15. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Arcangeli G; Fowler J; Gomellini S; Arcangeli S; Saracino B; Petrongari MG; Benassi M; Strigari L Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1013-21. PubMed ID: 20447774 [TBL] [Abstract][Full Text] [Related]
16. Rectal radiation dose-reduction techniques in prostate cancer: a focus on the rectal spacer. Leiker AJ; Desai NB; Folkert MR Future Oncol; 2018 Nov; 14(26):2773-2788. PubMed ID: 29939069 [TBL] [Abstract][Full Text] [Related]
17. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587 [TBL] [Abstract][Full Text] [Related]
18. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer. Cheng JC; Schultheiss TE; Nguyen KH; Wong JY Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):351-7. PubMed ID: 18164841 [TBL] [Abstract][Full Text] [Related]
19. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity. Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959 [TBL] [Abstract][Full Text] [Related]
20. [Prostate cancer: what treatment techniques for which tumors? Ethical and methodological issues]. de Crevoisier R; Castelli J; Guérif S; Pommier P; Créhange G; Chauvet B; Lagrange JL Cancer Radiother; 2014 Oct; 18(5-6):369-78. PubMed ID: 25199865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]